ambossIconambossIcon

Cardiac glycosides

Last updated: September 6, 2023

Summarytoggle arrow icon

Cardiac glycosides are drugs that inhibit the Na+/K+- ATPase found on the outer cell surface. Digoxin is the only drug of this class that is commonly used in clinical settings. The main indications for digoxin treatment are atrial fibrillation and heart failure in treatment-resistant cases. Because cardiac glycosides have a narrow therapeutic index, close monitoring of serum concentrations is necessary. Typical symptoms of cardiac glycoside poisoning are nausea, vomiting, blurry vision, and cardiac arrhythmias. Overdose can quickly become life-threatening and swift treatment is vital. The first-line treatment for cardiac glycoside poisoning is administration of digoxin-specific antibodies.

See also “Digoxin poisoning.”

Overviewtoggle arrow icon

  • Drugs: digoxin, ouabain
  • Mechanism: inhibition of the cardiac and neuronal Na+/K+- ATPase
  • Onset of effect
    • Oral: 0.5–2 h
    • IV: 15–30 min
  • Half-life: 36–40 hours
  • Protein binding: 20–40%
  • Elimination: renal

References:[1][2][3][4]

Pharmacodynamicstoggle arrow icon

Cardiac glycosides inhibit Na+/K+-ATPase, increasing cardiac contractility and decreasing AV conduction and heart rate!

Cardiac glycoside poisoningtoggle arrow icon

Indicationstoggle arrow icon

References:[3][8]

Contraindicationstoggle arrow icon

References:[8]

We list the most important contraindications. The selection is not exhaustive.

Interactionstoggle arrow icon

Icon of a lock3 free articles left this month

Start a 5-day free trial or sign up for unlimited access.
 Evidence-based content, created and peer-reviewed by clinicians. Read the disclaimer